Esperion Reports Second Quarter 2022 Financial Results and Provides Company Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Esperion Therapeutics (ESPR) Misses Q2 EPS by 12c
August 2, 2022 7:06 AM EDTEsperion Therapeutics (NASDAQ: ESPR) reported Q2 EPS of ($1.05), $0.12 worse than the analyst estimate of ($0.93). Revenue for the quarter came in at $0 versus the consensus estimate of $18.58 million.
GUIDANCE:
2022 Financial Outlook
The Company is reaffirming its prior operational expense guidance.... More
